Biomissile, a clinical stage biotech company developing fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM) recently announced the first subject was successfully dosed on June 9, 2023 for BM219 in a Phase 1 trial. The administration was completed without any adverse event being observed. 
 
BM219 is a bispecific, broad-spectrum, inhalable anti-COVID-19 UDAB-M^TM molecule. The indications of BM219 are for both the treatment and post-exposure prophylaxis of COVID-19 infection. BM219 is effective against all circulating COVID-19 variants, from wild type to XBB and BQ1.1 in preclinical studies.

Links to the Chinese news and more info about BM219:

https://mp.weixin.qq.com/s/mlyuj1ebhMzEkyBVaKQoXg

https://mp.weixin.qq.com/s/BGrbGNW2QnHzgI56OkNqyg